Comparison of the efficacy of domestic and imported momelotinib

Momelotinib is a new type of JAK1/2 inhibitor that has been approved for marketing overseas in recent years. It also has ACVR1 inhibitory effects. Its clinical positioning is mainly to improve anemia symptoms and general discomfort in patients with myelofibrosis (MF). For Chinese patients, a current focus is the difference in efficacy between imported and domestically produced drugs.

First of all, from the current status of the drug, the original drug of molotinib was developed by overseas pharmaceutical companies and has been approved for marketing in Europe and the United States. It has a variety of specifications to choose from, such as 100mg30 tablets, 150mg30 tablets and 200mg*30 tablets. However, currently in the Chinese market, molotinib has not yet been officially launched. There are no imported original drugs for sale, and no domestic generic drugs have been approved. Therefore, if domestic patients want to use it, they usually need to obtain it through overseas drug purchase channels or overseas medical channels, which limits accessibility to a certain extent.

In terms of efficacy, imported original drugs have undergone complete clinical trial verification, have relatively sufficient efficacy and safety data, and have stable preparation processes, making it easier to ensure patient compliance during treatment. In comparison, if domestic generic drugs can be put on the market in the future, their efficacy needs to be proven to be equivalent to the original drugs through consistency evaluation. Considering that China has gradually moved closer to international standards in the production process and quality control of generic drugs, theoretically there should be no significant difference in efficacy between domestically produced versions in the future, but they may be more advantageous in terms of price, thereby improving long-term affordability for patients.

Another aspect that deserves attention is supply and health insurance coverage. Imported drugs often have problems with high prices and difficulty in reimbursement when they first enter the Chinese market. However, once domestic generic drugs are launched, they will usually be included in the medical insurance catalog at an accelerated pace, which is of great significance to reducing the financial burden on patients.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib